Expansion of US Office

Bath, UK, January 8, 2016. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Bob Johnston as Chief Financial Officer, who will be based in the recently opened Boston office.

Bob has over 20 years of experience in the life science industry where he has a very successful track record in all aspects of growing companies.  His experience includes substantial equity and debt fund raisings, mergers/sales and acquisitions and taking companies public in the US.  His extensive CFO expertise includes the successful growth and acquisition of Ascension Orthopedics, Tutogen Medical and Oncormed and the successful acquisition of Scientific Protein Laboratories.  Bob will be located at the Boston office along with Keith Stauffer, VP Sales and Marketing, whose appointment was announced in November.

John Clarkson, CEO of Atlas Genetics, said:  “We are delighted to welcome Bob to Atlas Genetics.  With the CE mark for our first product expected shortly, Bob’s broad experience in the life sciences industry will be invaluable to Atlas Genetics as we enter our next phase of growth.”

Bob Johnston, CFO of Atlas Genetics, added: “With the anticipated launch of the Company's first product, 2016 will be an important year and I look forward to working with John and his team in growing Atlas Genetics into a major force in point of care molecular diagnostics.  I believe the Company has great potential in this field.”

Atlas Genetics appoints Keith Stauffer as VP Sales & Marketing

Bath, UK, November 16th 2015. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Keith Stauffer as VP Sales and Marketing. Based in the newly opened Boston office, Keith will lead the launch and commercialisation of the Atlas Genetics io® System.

Since 2011, Keith has been VP Marketing for Infectious Diseases at Alere Inc., where most recently he was responsible for developing the pricing strategy, aligning reimbursement initiatives and marketing campaigns for the launch of the Alere i ™ Flu test, the first CLIA waived POC molecular rapid flu test. In the first 12 months from launch over 2,500 instruments were placed. Previously, Keith was VP Sales for the Clinical Products Group within Alere, which included infectious disease POC tests. Prior to Alere, Keith worked for Thermo Electron in their Point of Care and Rapid Diagnostics division.

John Clarkson, CEO, said: “We are delighted to welcome Keith to Atlas Genetics. With CE mark approval for our first test anticipated around the end of this year we are about to enter the next phase in the growth of the Company. Keith’s expertise in the development and roll-out of commercialisation strategies within this field will be invaluable as we bring our ultra-rapid point of care tests for Sexually Transmitted Infections and Hospital Acquired Infections to market.”

Keith Stauffer, VP Sales & Marketing, added: “The io® System developed by Atlas Genetics offers a unique solution to the delivery of high quality testing results at the point of care. I believe that this system will transform the treatment and management of patients with infectious diseases across a range of clinical areas and I look forward to working with John and his team to launch the io® System in Europe and the US.”